JP2024525843A5 - - Google Patents
Info
- Publication number
- JP2024525843A5 JP2024525843A5 JP2024502438A JP2024502438A JP2024525843A5 JP 2024525843 A5 JP2024525843 A5 JP 2024525843A5 JP 2024502438 A JP2024502438 A JP 2024502438A JP 2024502438 A JP2024502438 A JP 2024502438A JP 2024525843 A5 JP2024525843 A5 JP 2024525843A5
- Authority
- JP
- Japan
- Prior art keywords
- glu
- lys
- pharmaceutically acceptable
- acceptable salt
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222747P | 2021-07-16 | 2021-07-16 | |
| US63/222,747 | 2021-07-16 | ||
| PCT/US2022/073793 WO2023288313A1 (en) | 2021-07-16 | 2022-07-15 | Compositions including multi-agonist peptides and methods of manufacture and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525843A JP2024525843A (ja) | 2024-07-12 |
| JP2024525843A5 true JP2024525843A5 (cg-RX-API-DMAC7.html) | 2025-07-24 |
Family
ID=84919777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502438A Pending JP2024525843A (ja) | 2021-07-16 | 2022-07-15 | マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230203100A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4370537A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024525843A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022311018A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226003A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023288313A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240059753A1 (en) * | 2022-07-15 | 2024-02-22 | Pep2Tango Therapeutics Inc. | Compositions including multi-agonist peptides and methods of manufacture and use |
| AU2024218747A1 (en) * | 2023-02-10 | 2025-08-28 | Hangzhou Sciwind Biosciences Co., Ltd. | Polypeptide and derivative thereof, composition, and use thereof |
| TWI926512B (zh) * | 2023-11-30 | 2026-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| US20250236656A1 (en) * | 2023-12-12 | 2025-07-24 | Amide Technologies | Multimeric polypeptides and uses thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| KR102966075B1 (ko) * | 2024-11-19 | 2026-05-19 | (주)케어젠 | 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도 |
| KR102991397B1 (ko) | 2024-11-29 | 2026-07-21 | 노보 노르디스크 에이/에스 | Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2597649A1 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| US8598314B2 (en) * | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| SI2864350T1 (en) * | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| EP3856768A2 (en) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| IL296219A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
-
2022
- 2022-07-15 JP JP2024502438A patent/JP2024525843A/ja active Pending
- 2022-07-15 WO PCT/US2022/073793 patent/WO2023288313A1/en not_active Ceased
- 2022-07-15 AU AU2022311018A patent/AU2022311018A1/en active Pending
- 2022-07-15 CA CA3226003A patent/CA3226003A1/en active Pending
- 2022-07-15 EP EP22843079.9A patent/EP4370537A4/en active Pending
- 2022-07-15 US US17/812,993 patent/US20230203100A1/en active Pending